MAZZOTTA, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 975
EU - Europa 636
AS - Asia 229
AF - Africa 9
SA - Sud America 4
Totale 1.853
Nazione #
US - Stati Uniti d'America 965
SE - Svezia 314
IT - Italia 174
SG - Singapore 105
IN - India 63
DE - Germania 35
FI - Finlandia 31
CN - Cina 27
GB - Regno Unito 21
ID - Indonesia 19
BG - Bulgaria 12
RO - Romania 10
IE - Irlanda 8
RU - Federazione Russa 8
TG - Togo 8
CA - Canada 7
IR - Iran 7
FR - Francia 5
HK - Hong Kong 5
UA - Ucraina 5
NL - Olanda 4
AT - Austria 3
CH - Svizzera 2
JO - Giordania 2
MX - Messico 2
AR - Argentina 1
BE - Belgio 1
BO - Bolivia 1
CL - Cile 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EE - Estonia 1
KZ - Kazakistan 1
PL - Polonia 1
PT - Portogallo 1
ZA - Sudafrica 1
Totale 1.853
Città #
Stockholm 175
Fairfield 137
Singapore 71
Ashburn 69
Chandler 67
Seattle 61
Woodbridge 61
Rome 60
Houston 55
Santa Clara 55
Wilmington 51
Cambridge 48
Princeton 30
Helsinki 29
San Paolo di Civitate 26
Ann Arbor 19
Jakarta 18
Sacramento 16
Andover 15
Lawrence 15
Millbury 15
New York 14
Boston 12
Bremen 12
Sofia 12
Dearborn 11
Milan 11
San Diego 11
Lomé 8
Norwalk 8
Surrey 7
Beijing 6
Dublin 6
Padova 6
Boardman 4
Falkenstein 4
Toronto 4
Bühl 3
Dallas 3
Glasgow 3
Hong Kong 3
Leawood 3
Mannheim 3
Moscow 3
Ottawa 3
Perugia 3
Phoenix 3
Plano 3
Ponte San Pietro 3
Zanjan 3
Amman 2
Birmingham 2
Central 2
Formello 2
Frankfurt am Main 2
Fremont 2
Fuzhou 2
Groningen 2
Kashan 2
London 2
Los Angeles 2
Magenta 2
Nuremberg 2
Santa Maria Capua Vetere 2
Torino 2
Almaty 1
Augusta 1
Avellino 1
Balasore 1
Bern 1
Carlentini 1
Chieti 1
Corridonia 1
Des Moines 1
Edinburgh 1
Falls Church 1
Federal 1
Guangzhou 1
Guayaquil 1
Guidonia 1
Guidonia Montecelio 1
Hefei 1
Jacksonville 1
Kish 1
Kraainem 1
La Paz 1
Levallois-perret 1
Liverpool 1
Locorotondo 1
Lu'an 1
Menlo Park 1
Mexico City 1
Muizenberg 1
Nanchang 1
Nanjing 1
Newark 1
Prescot 1
Pune 1
Redwood City 1
Santiago Metropolitan 1
Totale 1.333
Nome #
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial 189
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 108
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab 107
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 100
Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer 95
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab 93
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting 70
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification 66
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden 65
KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy 62
Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: current evidence and literature-based meta-analysis of randomized trials 61
Immunotherapy in HER2-positive breast cancer. state of the art and future perspectives 60
Role of chemotherapy in vulvar cancers: time to rethink standard of care? 56
CDKN2A/B gene loss and MDM2 alteration as a potential molecular signature for hyperprogressive disease in advanced NSCLC: A next-generation-sequencing approach 56
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes 55
Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting. a survey about Italian physicians’ practice 54
null 50
null 50
null 50
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives 48
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience 48
Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: A single-center experience and review of the literature 47
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 44
Observational multicenter study on the prognostic relevance of coagulation activation in risk assessment and stratification in locally advanced breast cancer. Outline of the arias trial 42
Circulating hpv dna in the management of oropharyngeal and cervical cancers: current knowledge and future perspectives 38
KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed. Reply to “KEAP1-NFE2L2–Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis” 31
Burnout of health care providers during the covid-19 pandemic: Focus on medical oncologists 26
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study 25
Neoadjuvant endocrine therapy in breast cancer. Current knowledge and future perspectives 25
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 22
The use of fentanyl in pain management in head and neck cancer patients. a narrative review 22
null 21
Prognostic relevance of neutrophil to lymphocyte ratio (Nlr) in luminal breast cancer: A retrospective analysis in the neoadjuvant setting 21
Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer 20
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study 19
Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report 17
Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors 17
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study 15
Transcriptional phenocopies of deleterious KEAP1 mutations correlate with survival outcomes in lung cancer treated with immunotherapy 13
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 10
Pulmonary Fibrosis after Pegylated Liposomal Doxorubicin in Elderly Patient with Cutaneous Angiosarcoma 7
null 4
Concise Review: Gene of The Month {KEAP}1-mutant non-small cell lung cancer: the catastrophic failure of a cell-protecting hub 2
Totale 2.031
Categoria #
all - tutte 7.580
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.580


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020158 0 0 0 0 0 0 36 29 32 32 15 14
2020/2021202 21 7 6 11 5 5 12 31 13 69 20 2
2021/2022361 5 4 11 20 75 31 3 28 20 19 97 48
2022/2023449 101 91 38 30 59 37 14 30 26 6 13 4
2023/2024209 7 24 3 15 23 36 19 26 3 23 19 11
2024/2025455 174 55 43 59 82 38 4 0 0 0 0 0
Totale 2.031